Oneness Biotech Co., Ltd. (4743.TWO)

157.50 -2.50 (-1.56%) At close: 01:30PM CST

Oneness Biotech Co., Ltd.

No.236, Xinyi Road
11th Floor Sec. 4 Da’an district
Taipei 106
Taiwan
886 2 2703 1098
https://www.onenessbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nien-Yi Chen	Deputy General Manager of Antibody New Drug Division;	6.03M	N/A	N/A
Ms. Shuling Cheng Ph.D.	President	N/A	N/A	N/A
Ms. Wen-Tzu Hsiao	Acting Spokesperson & Senior Manager of Finance Department	N/A	N/A	N/A
Wen Ci Xiao	Accounting Supervisor	N/A	N/A	N/A
Dr. Jui-Ching Chen Ph.D.	Director of New Drug Development Department	N/A	N/A	N/A
Mr. Kung-Ming Lu	Director of Operation Center	N/A	N/A	N/A
Mr. Tzu-Chun Yang	Associate General Manager of Information Technology Department	2.14M	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase I clinical trials; and FB918 for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

Corporate governance

Oneness Biotech Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.